Disclosure under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Annual Secretarial Compliance Report for the Financial Year ended March 31, 2025.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under SEBI Listing Regulations. The report, issued by Mehta & Mehta, Company Secretaries, covers the company's adherence to SEBI regulations, circulars, the SEBI Act, and the Securities Contracts Regulation Act. The company received a clean bill of health with no deviations, non-compliances, penalties, or observations reported across all 13 compliance areas examined, including secretarial standards, insider trading, related party transactions, and subsidiary disclosures. No actions were taken by SEBI or stock exchanges against the company, its promoters, directors, or subsidiaries during the review period.
This is a routine annual compliance confirmation with no material impact on shareholders or stock price. It reinforces that Emcure is in good regulatory standing with no governance red flags for the year.